Amethyst Radiotherapy orders Elekta cancer treatment solutions for European expansion

High-end linear accelerators to be delivered to clinics in France, Poland and
Romania
STOCKHOLM, Sweden, November 18, 2015 – Elekta (EKTA-B.ST) will deliver advanced
radiotherapy equipment and services to Amethyst Radiotherapy, a private cancer
treatment network serving Western and Central Europe. The value of the order,
approximately EUR 28 million, was booked in the second quarter of Elekta’s
fiscal year.

With a focus on radiation oncology, Amethyst Radiotherapy’s medical teams
treated over 4,000 patients in 2014 at clinics in France, Poland and Romania. It
continues to be one of Europe’s fastest growing medical networks and expects to
have 20 clinics and a total of 42 linear accelerators by the end of 2020.

Barbara Werchowiecka-Rusinek, Amethyst Radiotherapy’s CEO, says: “In order to
treat patients well and safely, we needed a proven and experienced technological
partner. Therefore we chose Elekta to equip our radiotherapy centers in
Bucharest and Cluj (Romania) and Krakow (Poland), and now even as we upgrade our
centers in France.”

She adds: “In May this year, we performed our first radiosurgery, removing a
tumor in a patient’s brain and saving her life. We are the only ones to offer
such advanced therapeutic treatment in the regions where we are located, which
is a great benefit for patients. Our success is due in part to our cooperation
with Elekta and the high precision and reliability of its accelerators, as well
as the professionalism of the team who supervises their operation.”

Francois Pointurier, Senior Vice President, Region Europe & AFLAME at Elekta,
says: “According to the Lancet Oncology
Commission[1] (http://file///C:/Users/sewalkri/Documents/Corporate%20Comm/PR/Ame
t 
hyst/Amethyst%20Radiotherapy_final_EN.doc#_ftn1) there are substantial health
and economic benefits in using radiotherapy and huge investments need to be made
to meet the world’s needs. We are pleased that Amethyst sees the potential of
radiotherapy and that they have chosen Elekta as their supplier.”

Rashid Oozeer, Chief Medical Physicist at Amethyst Radiotherapy, says: “Amethyst
Radiotherapy is helping to satisfy the demand for radiation therapy treatment in
Europe as it opens new clinics and furnishes existing sites with the most
advanced radiotherapy equipment and software. Elekta delivers the technologies
our clinics rely on, such as intensity modulated radiotherapy (IMRT), volumetric
modulated arc therapy (VMAT), stereotactic radiotherapy, image-guided
radiotherapy (IGRT) and high definition brachytherapy.”

As the company expands in Western and Central Europe, it will equip its
treatment centers with state-of-the-art devices, including Versa HD™, the most
modern linear accelerator on the market. In addition to Versa HD, the agreement
also includes Elekta Infinity™ linear accelerators, brachytherapy devices,
MOSAIQ® oncology information system and services.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on November 18, 2015.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.

----------------------------------------------------------------------

[1] (http://file///C:/Users/sewalkri/Documents/Corporate%20Comm/PR/Amethyst/Amet
h 
yst%20Radiotherapy_final_EN.doc#_ftnref1) Expanding Global Access to
Radiotherapy DOI: http://dx.doi.org/10.1016/S1470-2045(15)00222-3